Skip to main content

Eligibility Limited for Anti-β Amyloid mAbs in Seniors With MCI

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

FRIDAY, Aug. 18, 2023 -- Older adults with cognitive impairment have limited eligibility for anti-β amyloid monoclonal antibodies when applying clinical trial criteria, according to a study published online Aug. 16 in Neurology.

Rioghna R. Pittock, from the Mayo Clinic in Rochester, Minnesota, and colleagues applied the clinical trial eligibility criteria for lecanemab and aducanumab treatment to participants with early Alzheimer Disease from the population-based Mayo Clinic Study of Aging (MCSA). The study sample included 237 MCSA participants with mild cognitive impairment (MCI) or mild dementia and increased brain amyloid burden.

The researchers found that the sample was reduced to 112 participants (47.3 percent) with the lecanemab trial's inclusion criteria and was further reduced to 19 (8 percent) with the trial's exclusion criteria. Instead of applying additional cognitive criteria, modifying the exclusion criteria to include all participants with MCI resulted in 17.4 percent of participants with MCI being eligible for lecanemab. Overall, 104 participants met the clinical trial inclusion criteria for aducanumab (43.9 percent). The number of eligible participants was further reduced to 12 (5.1 percent) with the aducanumab trial's exclusion criteria. Chronic conditions and neuroimaging findings were common exclusions.

"Our study results show only a small percentage of people with early Alzheimer's disease may be eligible to receive treatment, mostly due to chronic health conditions and brain scan abnormalities common in older adults," study author Maria Vassilaki, M.D., Ph.D., also of the Mayo Clinic, said in a statement. "Additional research is needed to examine the safety and efficacy of monoclonal antibodies targeting amyloid-β plaques in larger, more diverse populations."

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Self-, Partner-Reported Cognitive Decline Linked to Tau

THURSDAY, May 30, 2024 -- Individuals who self-report and whose partners report cognitive decline have greater tau, which is driven by elevated beta-amyloid (Aβ), according...

Socioeconomic Status Transitions Tied to Dementia Risk

THURSDAY, May 23, 2024 -- Upward and downward socioeconomic status (SES) transitions are associated with the risk for dementia and the length of dementia-free periods during the...

Ultraprocessed Food Consumption Linked to Cognitive Impairment, Stroke

THURSDAY, May 23, 2024 -- The levels of food processing is associated with cognitive impairment and stroke, according to a study published online May 22 in Neurology. Varun M...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.